Rani Historical Balance Sheet
RANI Stock | USD 1.39 0.01 0.71% |
Trend analysis of Rani Therapeutics Holdings balance sheet accounts such as Total Stockholder Equity of 15.5 M, Net Tangible Assets of 44.5 M, Property Plant And Equipment Net of 6 M or Current Deferred Revenue of 1.5 M provides information on Rani Therapeutics' total assets, liabilities, and equity, which is the actual value of Rani Therapeutics to its prevalent stockholders. By breaking down trends over time using Rani Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Rani Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Rani Therapeutics is a good buy for the upcoming year.
Rani |
About Rani Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Rani Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Rani Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Rani Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Rani currently owns. An asset can also be divided into two categories, current and non-current.
Rani Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Rani Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Rani Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Rani Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Rani Therapeutics Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Rani Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Rani Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rani Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. As of now, Rani Therapeutics' Net Tangible Assets are increasing as compared to previous years. The Rani Therapeutics' current Current Deferred Revenue is estimated to increase to about 1.5 M, while Other Current Liabilities is projected to decrease to under 1.4 M.
2023 | 2024 | 2025 (projected) | Short and Long Term Debt Total | 30.1M | 27.1M | 35.9M | Total Assets | 57.9M | 66.6M | 86.4M |
Rani Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Rani Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Rani Therapeutics balance sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 79.4M | 124.2M | 108.0M | 57.9M | 66.6M | 86.4M | |
Other Current Liab | 695K | 1.6M | 1.3M | 1.7M | 1.6M | 1.4M | |
Total Current Liabilities | 5.3M | 2.6M | 4.8M | 8.0M | 9.2M | 5.3M | |
Total Stockholder Equity | (113.3M) | 47.4M | 36.9M | 12.9M | 14.8M | 15.5M | |
Property Plant And Equipment Net | 4.5M | 4.6M | 7.1M | 6.8M | 7.8M | 6.0M | |
Net Debt | (69.3M) | (117.5M) | 3.2M | 24.2M | 21.8M | 22.9M | |
Retained Earnings | (114.0M) | (8.3M) | (38.9M) | (72.9M) | (83.8M) | (88.0M) | |
Accounts Payable | 537K | 1.1M | 1.5M | 648K | 745.2K | 863.1K | |
Cash | 73.1M | 117.5M | 27.0M | 5.9M | 5.3M | 5.0M | |
Non Current Assets Total | 4.5M | 4.6M | 7.1M | 7.1M | 8.1M | 6.5M | |
Cash And Short Term Investments | 73.1M | 117.5M | 98.5M | 48.5M | 55.8M | 77.9M | |
Liabilities And Stockholders Equity | 79.4M | 124.2M | 108.0M | 57.9M | 66.6M | 86.4M | |
Non Current Liabilities Total | 187.4M | 1.1M | 29.2M | 24.5M | 22.0M | 20.9M | |
Other Current Assets | 167K | 2.1M | 2.4M | 2.3M | 2.7M | 1.6M | |
Total Liab | 192.8M | 2.6M | 34.0M | 32.5M | 29.2M | 27.8M | |
Net Invested Capital | (109.6M) | 47.4M | 66.0M | 42.2M | 48.6M | 51.0M | |
Property Plant And Equipment Gross | 6.3M | 6.9M | 7.1M | 10.5M | 12.1M | 8.0M | |
Total Current Assets | 74.9M | 119.6M | 100.9M | 50.8M | 58.5M | 79.9M | |
Accumulated Other Comprehensive Income | (849.0K) | (124.2M) | (73K) | (12K) | (13.8K) | (14.5K) | |
Net Working Capital | 69.6M | 117.0M | 96.1M | 42.9M | 49.3M | 74.6M |
Currently Active Assets on Macroaxis
When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rani Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.